RT Journal Article
T1 The urgent need to recover MHC class I in cancers for effective immunotherapy.
A1 Garrido, Federico
A1 Aptsiauri, Natalia
A1 Doorduijn, Elien M
A1 Garcia Lora, Angel M
A1 van Hall, Thorbald
K1 Presentación de antígeno
K1 Genes clase I del complejo de histocompatibilidad (MHC)
K1 Antígenos de histocompatibilidad clase I
K1 Humanos
K1 Inmunoterapia
K1 Neoplasias
K1 Linfocitos T
K1 Escape del tumor
K1 Regulación hacia arriba
AB Immune escape strategies aimed to avoid T-cell recognition, including the loss of tumor MHC class I expression, are commonly found in malignant cells. Tumor immune escape has proven to have a negative effect on the clinical outcome of cancer immunotherapy, including treatment with antibodies blocking immune checkpoint molecules. Hence, there is an urgent need to develop novel approaches to overcome tumor immune evasion. MHC class I antigen presentation is often affected in human cancers and the capacity to induce upregulation of MHC class I cell surface expression is a critical step in the induction of tumor rejection. This review focuses on characterization of rejection, escape, and dormant profiles of tumors and its microenvironment with a special emphasis on the tumor MHC class I expression. We also discuss possible approaches to recover MHC class I expression on tumor cells harboring reversible/'soft' or irreversible/'hard' genetic lesions. Such MHC class I recovery approaches might well synergize with complementary forms of immunotherapy.
PB Elsevier
SN 0952-7915
YR 2016
FD 2016-04
LK http://hdl.handle.net/10668/2236
UL http://hdl.handle.net/10668/2236
LA en
NO Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr. Opin. Immunol.. 2016                         ; 39:44-51
NO Journal Article; Review;
DS RISalud
RD Apr 18, 2025